KUALA LUMPUR, Jan 18 (Bernama) -- Global biopharmaceutical company Terns Pharmaceuticals Inc (Terns) has appointed Erin Quirk, M.D. as chief medical officer.
The company, in a statement, said Dr Quirk brings more than two decades of clinical medicine and drug development experience, most recently serving as vice president of Clinical Research at Gilead Sciences.
She oversaw all phases of clinical development for Gilead’s HIV treatment, prevention and cure franchise and was responsible for strategy and life-cycle maintenance for the company’s HIV portfolio, advancing multiple compounds and combination products into clinical development and through the approval process.
“We are delighted to have Erin join us at this critical time in our company’s growth, as her proven leadership and background in both early and late-stage drug development make her well suited to lead the growing Terns clinical development team,” said president and chief executive officer of Terns, Weidong Zhong, Ph.D.
Terns is based in San Mateo, California, and Shanghai, China. The company is committed to discover and develop molecularly targeted, oral, small molecule drugs to treat liver disease and cancer. More details at https://ternspharma.com.
-- BERNAMA
No comments:
Post a Comment